製品番号: HY-15826

SGC-CBP30

24 Cited Publications

カスタマーレビュー

Based on 24 publication(s) in Google Scholar

SGC-CBP30, a chemical probe, is a potent and highly selective CBP/p300 bromodomain (K_ds of 21 nM and 32 nM for CBP and p300, respectively) inhibitor, displaying 40-fold selectivity over the first bromodomain of BRD4 [BRD4(1)] bound. SGC-CBP30 strongly reduces secretion of IL-17A in Th17 cells and has anti-inflammatory effects.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.60%
CAS 番号: 1613695-14-9
分子式: C₂₈H₃₃ClN₄O₃
分子量:509.04

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

SGC-CBP30 構造式

CAS 番号: 1613695-14-9

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 体内実験
化学情報
Publications (24)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target

CBP/p300

Epigenetic Reader Domain アイソフォーム固有の製品をすべて表示 :

Histone Acetyltransferase アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
CWR22R	IC₅₀	>10 μM Compound: CBP30	Antiproliferative activity against human 22Rv1 cells incubated for 5 days by CCK-8 method Antiproliferative activity against human 22Rv1 cells incubated for 5 days by CCK-8 method	[PMID: 35569250]
HEK293	IC₅₀	2.8 μM Compound: 2; SGC-CBP30	Inhibition of Halo-tagged histone H3.3 binding to NanoLuc luciferase conjugated CBP (unknown origin) expressed in HEK293 cells after overnight incubation by BRET assay Inhibition of Halo-tagged histone H3.3 binding to NanoLuc luciferase conjugated CBP (unknown origin) expressed in HEK293 cells after overnight incubation by BRET assay	[PMID: 27682507]
MCF7	IC₅₀	2.39 μM Compound: CBP30	Antiproliferative activity against human MCF7 cells incubated for 5 days by CCK-8 method Antiproliferative activity against human MCF7 cells incubated for 5 days by CCK-8 method	[PMID: 35569250]
MOLM-13	IC₅₀	1.53 μM Compound: CBP30	Cytotoxicity against human MOLM-13 cells assessed as cell growth inhibition incubated for 5 days by CellTiter-Glo luminescence assay Cytotoxicity against human MOLM-13 cells assessed as cell growth inhibition incubated for 5 days by CellTiter-Glo luminescence assay	[PMID: 33872011]
OPM-2	IC₅₀	2.64 μM Compound: CBP30	Antiproliferative activity against human OPM-2 cells incubated for 5 days by CCK-8 method Antiproliferative activity against human OPM-2 cells incubated for 5 days by CCK-8 method	[PMID: 35569250]
RKO	IC₅₀	1.5 μM Compound: 11; SGC-CBP30	Inhibition of doxorubicin-stimulated p53 (unknown origin) expressed in human RKO cells preincubated for 24 hrs followed by addition of doxorubicin for 16 hrs by luciferase reporter assay Inhibition of doxorubicin-stimulated p53 (unknown origin) expressed in human RKO cells preincubated for 24 hrs followed by addition of doxorubicin for 16 hrs by luciferase reporter assay	[PMID: 26572217]
SCC-9	IC₅₀	6.42 μM Compound: CBP30	Antiproliferative activity against human SCC-9 cells incubated for 5 days by CCK-8 method Antiproliferative activity against human SCC-9 cells incubated for 5 days by CCK-8 method	[PMID: 35569250]

体外実験

In ankylosing spondylitis and psoriatic arthritis condition, SGC-CBP30 inhibits IL-17A secretion by Th17 cells. Transcriptional profiling of human T cells after SGC-CBP30 treatment shows a much more restricted effect on gene expression than that observed with the pan-BET (bromo and extraterminal domain protein family) bromodomain inhibitor JQ1^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

SGC-CBP30 treatment slightly alleviates alveolar bronchial fibrosis induced by NSC-125066. SGC-CBP30 plus CQ-061 dramatically reduces alveolar bronchial fibrosis. The ELISA of cytokines IL-4 and IFN-γ in BALF demonstrates that combination of SGC-CBP300 and CQ-061 suppresses the activation of IL-4 as well as IFN-γ in NSC-125066 induced IPF murine models to nearly normal levels^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Sprague-Dawley (SD) rats (aged 3-4 weeks) injected with NSC-125066^[2]
Dosage:

25 mg/kg
Administration:

Oral administration; daily; for 14 days
Result:

Slightly alleviated alveolar bronchial fibrosis induced by NSC-125066.

化学情報

CAS 番号 1613695-14-9
性状 Solid
分子量 509.04
分子式 C₂₈H₃₃ClN₄O₃
Color White to yellow
SMILES

C[C@H](N1CCOCC1)CN2C(CCC3=CC=C(OC)C(Cl)=C3)=NC4=CC(C5=C(C)ON=C5C)=CC=C42
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (24)

All Histological Imaging/StainingRT-PCRCell Proliferation/Viability AssayWBELISA

Sort by:

Journal Impact Factor

Immunity

Small-molecule CBP/p300 histone acetyltransferase inhibition mobilizes leukocytes from the bone marrow via the endocrine stress response. [Abstract]

2024 Feb 13;57(2):364-378.e9. PMID: 38301651
Nat Commun

Transcription factor 19 modulates fatty acid elongation and unfolded protein response to attenuate palmitic acid-induced hepatic dysfunction. [Abstract]

2026 Apr 22;17(1):5596. PMID: 42020413
Nat Commun

Human iPSC-based Modeling of Pulmonary Fibrosis Reveals p300/CBP Inhibition Suppresses Alveolar Transitional Cell State. [Abstract]

2026 Feb 12;17(1):1214. PMID: 41680175
Nat Commun

Isonicotinylation is a histone mark induced by the anti-tuberculosis first-line drug isoniazid. [Abstract]

2021 Sep 20;12(1):5548. PMID: 34545082
J Adv Res

Elevated EBF2 in mouse but not pig drives the progressive brown fat lineage specification via chromatin activation. [Abstract]

2025 Oct:76:327-344. PMID: 39736442

SGC-CBP30 purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 Oct:76:327-344. [Abstract]

SGC-CBP30 (7.5 μg/mL, for 8 days) inhibits adipogenic differentiation in EBF2-overexpressing cells, as assessed by Oil Red O staining.

SGC-CBP30 purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 Oct:76:327-344. [Abstract]

SGC-CBP30 (7.5 μg/mL, for 8 days) downregulated the expression of brown fat marker genes (BMP7, CIDEA, and PPARγ) and mitochondrial markers (PGC1α, Cox7a1, and Cox5b) induced in EBF2-overexpressing cells.
Cell Discov

Single-cell transcriptomics reveals intestinal cell heterogeneity and identifies Ep300 as a potential therapeutic target in mice with acute liver failure. [Abstract]

2023 Jul 25;9(1):77. PMID: 37488127
Blood Cancer J

Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4. [Abstract]

2019 Feb 11;9(2):19. PMID: 30741931

SGC-CBP30 purchased from MedChemExpress. Usage Cited in: Blood Cancer J. 2019 Feb 11;9(2):19. [Abstract]

The combination of SGC-CBP30 (0.2 and 0.4 μM, 5 days) and Lenalidomide (10 μM, 5 days) exerted substantial synergy in reducing the viability of myeloma XG1LenRes cells.

SGC-CBP30 purchased from MedChemExpress. Usage Cited in: Blood Cancer J. 2019 Feb 11;9(2):19. [Abstract]

Immunoblotting assays detected the changes in IRF4, MYC, and STAT3 after treatment with Lenalidomide （10 μM） or SGC-CBP30 (0.2 and 0.4 μM) alone or in combination (day 3).

SGC-CBP30 purchased from MedChemExpress. Usage Cited in: Blood Cancer J. 2019 Feb 11;9(2):19. [Abstract]

SGC-CBP30 (0.2 and 0.4 μM, 2 days) treatment also reduced autocrine IL-6 production in XG1LenRes cells, both in the absence and presence of Lenalidomide (10 μM, 2 days).
Cell Death Dis

Pifithrin-μ sensitizes mTOR-activated liver cancer to sorafenib treatment. [Abstract]

2025 Jan 26;16(1):42. PMID: 39863613
Acta Pharmacol Sin

P300/CBP inhibition sensitizes mantle cell lymphoma to PI3Kδ inhibitor idelalisib. [Abstract]

2022 Feb;43(2):457-469. PMID: 33850273
Aging Dis

UPP1 Promotes Lung Adenocarcinoma Progression through Epigenetic Regulation of Glycolysis. [Abstract]

2022 Oct 1;13(5):1488-1503. PMID: 36186123
Int J Biol Macromol

Acetylation of GPRC5A at Lys348 facilitates cisplatin resistance and promotes the recurrence and poor prognosis in ovarian cancer. [Abstract]

2026 May:362:152113. PMID: 42009151
Hum Reprod Open

Human iPSCs derived from cryopreserved testicular somatic cells enable germline regeneration in childhood cancer survivors. [Abstract]

2026 Jun 3;2026(3):hoag054. PMID: 42389191
EMBO J

Acetylation of TIR domains in the TLR4-Mal-MyD88 complex regulates immune responses in sepsis. [Abstract]

2024 Nov;43(21):4954-4983. PMID: 39294473
Br J Pharmacol

Dual pharmacological targeting of coactivator-associated arginine methyltransferase 1 (CARM1) and salt inducible kinase (SIK) drives ketogenesis in both hepatocytes and mice. [Abstract]

2026 Apr 29. PMID: 42055601
Cell Syst

Integrated time-series analysis and high-content CRISPR screening delineate the dynamics of macrophage immune regulation. [Abstract]

2025 Aug 20;16(8):101346. PMID: 40782800
Virulence

Zika virus promotes CCN1 expression via the CaMKIIα-CREB pathway in astrocytes. [Abstract]

2020 Dec;11(1):113-131. PMID: 31957543
Int J Mol Sci

Hypoxia Increases ATX Expression by Histone Crotonylation in a HIF-2α-Dependent Manner. [Abstract]

2023 Apr 11;24(8):7031. PMID: 37108194
Mol Neurobiol

Gcm1 Orchestrates Lef1 Expression in Folate Deficiency-Induced Neural Tube Defects. [Abstract]

2025 Nov 11;63(1):29. PMID: 41217685
iScience

Global isonicotinylome analysis identified SMAD3 isonicotinylation promotes liver cancer cell epithelial-mesenchymal transition and invasion. [Abstract]

2024 Aug 21;27(9):110775. PMID: 39286495
Cytotechnology

EP300/CREBBP induces osteogenic differentiation of valve interstitial cells by promoting the SPP1 expression in calcific aortic valve disease. [Abstract]

2025 Oct;77(5):168. PMID: 40873695
bioRxiv

2025 Oct 11.
Patent

US20230255966A1.
Patent

US20180263995A1.
Methods Mol Biol

Methods for High-throughput Drug Combination Screening and Synergy Scoring. [Abstract]

2018:1711:351-398. PMID: 29344898

溶剤 & 溶解度

体外:

DMSO : 66.67 mg/mL (130.97 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.9645 mL

9.8224 mL

19.6448 mL

5 mM

0.3929 mL

1.9645 mL

3.9290 mL

10 mM

0.1964 mL

0.9822 mL

1.9645 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (4.91 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.91 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (277 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Hammitzsch A, et al. CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses. Proc Natl Acad Sci U S A. 2015 Aug 25;112(34):10768-73. [Content Brief]

[2]. Tao J, Inhibition of EP300 and DDR1 synergistically alleviates pulmonary fibrosis in vitro and in vivo. Biomed Pharmacother. 2018 Oct;106:1727-1733. [Content Brief]

[3]. Hay DA, et al. Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains. J Am Chem Soc. 2014 Jul 2;136(26):9308-19. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.9645 mL	9.8224 mL	19.6448 mL	49.1121 mL
	5 mM	0.3929 mL	1.9645 mL	3.9290 mL	9.8224 mL
	10 mM	0.1964 mL	0.9822 mL	1.9645 mL	4.9112 mL
	15 mM	0.1310 mL	0.6548 mL	1.3097 mL	3.2741 mL
	20 mM	0.0982 mL	0.4911 mL	0.9822 mL	2.4556 mL
	25 mM	0.0786 mL	0.3929 mL	0.7858 mL	1.9645 mL
	30 mM	0.0655 mL	0.3274 mL	0.6548 mL	1.6371 mL
	40 mM	0.0491 mL	0.2456 mL	0.4911 mL	1.2278 mL
	50 mM	0.0393 mL	0.1964 mL	0.3929 mL	0.9822 mL
	60 mM	0.0327 mL	0.1637 mL	0.3274 mL	0.8185 mL
	80 mM	0.0246 mL	0.1228 mL	0.2456 mL	0.6139 mL
	100 mM	0.0196 mL	0.0982 mL	0.1964 mL	0.4911 mL

Keywords

SGC-CBP30

24 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

SGC-CBP30

Reprogramming Compound Library

Chemical Probe Library

Anti-Blood Cancer Compound Library

Antidepressant Compound Library

Anti-Pulmonary Fibrosis Compound Library

Highly Selective Inhibitors Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Lactylation Compound Library

Epigenetics Compound Library Mini

Epigenetics Compound Library

Immunology/Inflammation Compound Library

Histone Modification Research Compound Library

MedChemExpress（MCE）の使用を引用している文献 SGC-CBP30

Epigenetic Reader Domain アイソフォーム固有の製品をすべて表示

Histone Acetyltransferase アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (24)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

SGC-CBP30

Reprogramming Compound Library

Chemical Probe Library

Anti-Blood Cancer Compound Library

Antidepressant Compound Library

Anti-Pulmonary Fibrosis Compound Library

Highly Selective Inhibitors Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Lactylation Compound Library

Epigenetics Compound Library Mini

Epigenetics Compound Library

Immunology/Inflammation Compound Library

Histone Modification Research Compound Library

MedChemExpress（MCE）の使用を引用している文献 SGC-CBP30

Epigenetic Reader Domain アイソフォーム固有の製品をすべて表示

Histone Acetyltransferase アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (24)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

SGC-CBP30 関連分類

HY-15826 関連分類